NCT05825443View on ClinicalTrials.gov

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2029

Conditions
ImmunotherapyChemotherapy
Interventions
DRUG

Camrelizumab

Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.

Trial Locations (1)

510515

RECRUITING

Nanfang Hospital, Southern Medical University, Guandong

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Nanfang Hospital, Southern Medical University

OTHER